Discover and read the best of Twitter Threads about #RheumMadness
Most recents (4)
So many amazing teams, having trouble filling out my #RheumMadness bracket!
2021: I thought the tournament came down to clinical trials vs scientific discoveries
Spoiler alert: clinical trials won (😢)
2022: past vs present vs future?
🧵
2021: I thought the tournament came down to clinical trials vs scientific discoveries
Spoiler alert: clinical trials won (😢)
2022: past vs present vs future?
🧵
Cells region: all about future implication
- NET: hot topic for a while now, but not yet ready for clinical utility
- Cytokine networks: may redefine how we classify rheumatic disease, though not anytime soon
- NET: hot topic for a while now, but not yet ready for clinical utility
- Cytokine networks: may redefine how we classify rheumatic disease, though not anytime soon
CAR-T and Pim kinases: both cancer therapies that can be repurposed for rheumatic disease
Both many years away from routine clinical care, though CAR-T has been successful in severe SLE!
Both many years away from routine clinical care, though CAR-T has been successful in severe SLE!
Time for a massive #RheumMadness thank you thread. This was a HUGE endeavor with so many contributors!
First, massive thanks to ALL OF YOU for participating! This project was always about inspiring collaborative learning. Thanks for playing, learning, debating, and sharing!
First, massive thanks to ALL OF YOU for participating! This project was always about inspiring collaborative learning. Thanks for playing, learning, debating, and sharing!
Second, huge thanks to the @RheumResearch Foundation for supporting this project through the Clinician Scholar Educator award. All aspiring educators in rheumatology, consider applying for this award! It connects you with an amazing community of educators.
Third, thank you to the fellow/resident members of the #RheumMadness leadership team: @AkiUdupa @GuyKatzMD @didemsayginmd and Allen Witt. It took a special kind of bravery to join this team and educate others on a podcast. You all are amazing!
How well did the #RheumRibbonPanel match #RheumMadness participants' predictions in the #SeronegativeSixteen?
Belimumab for LN vs. Anifrolumab
👩⚖️Panel:
Belimumab for LN: 5
Anifrolumab: 2
👩💻Participants:
80% picked belimumab for LN
More in 🧵 below 👇 (1/8)
Belimumab for LN vs. Anifrolumab
👩⚖️Panel:
Belimumab for LN: 5
Anifrolumab: 2
👩💻Participants:
80% picked belimumab for LN
More in 🧵 below 👇 (1/8)
PEXIVAS vs. Avacopan
👩⚖️Panel:
PEXIVAS: 3
Avacopan: 4
👩💻Participants:
66% picked avacopan
(2/8)
👩⚖️Panel:
PEXIVAS: 3
Avacopan: 4
👩💻Participants:
66% picked avacopan
(2/8)
IgG4-RD Classification Criteria vs. RP Subtypes
👩⚖️Panel:
IgG4-RD Classification Criteria: 5
RP Subtypes: 2
👩💻Participants:
77% picked IgG4-RD Classification Criteria
(3/8)
👩⚖️Panel:
IgG4-RD Classification Criteria: 5
RP Subtypes: 2
👩💻Participants:
77% picked IgG4-RD Classification Criteria
(3/8)
Still can't get over how good the #RheumMadness scouting reports are.
Common themes:
✅Most teams are convinced they will win their first round match-up (🤔)
✅Everyone is worried about AAV/SLE teams
Are we being blinded by the bright and shiny AAV/SLE trials?
I say yes.
🧵
Common themes:
✅Most teams are convinced they will win their first round match-up (🤔)
✅Everyone is worried about AAV/SLE teams
Are we being blinded by the bright and shiny AAV/SLE trials?
I say yes.
🧵
First, let's acknowledge that these trials (BLISS-LN, TULIP, PEXIVAS, ADVOCATE) are amazing and definitely worthy competitors. But clinical trials aren't new in #Rheumatology and the other teams offer so much to our field.
IgG4-RD Classification Criteria:
✅Disease many in our field don't understand
✅Describe common + rare manifestations
✅Emphasize IgG4-RD 🆚 mimickers
Think it's too rare to win? We don't even know prevalence (likely under-recognized)!
Hence the criteria...
✅Disease many in our field don't understand
✅Describe common + rare manifestations
✅Emphasize IgG4-RD 🆚 mimickers
Think it's too rare to win? We don't even know prevalence (likely under-recognized)!
Hence the criteria...
